Stockscreener 앱 받기
50.46
2.76%
-1.43
시간 외 거래:
50.63
0.17
+0.34%
전일 마감가:
$51.89
열려 있는:
$50.08
하루 거래량:
896.19K
Relative Volume:
0.85
시가총액:
$3.57B
수익:
-
순이익/손실:
$-141.43M
주가수익비율:
-20.53
EPS:
-2.4581
순현금흐름:
$-226.41M
1주 성능:
-7.55%
1개월 성능:
-25.21%
6개월 성능:
+113.99%
1년 성능:
+123.57%
1일 변동 폭
$49.37
$51.61
1주일 범위
$49.37
$61.20
52주 변동 폭
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
명칭
Structure Therapeutics Inc Adr
전화
(650) 457-1978
주소
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
50.46 | 3.68B | 0 | -141.43M | -226.41M | -2.4581 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-02 | 개시 | Citigroup | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-12-04 | 개시 | H.C. Wainwright | Buy |
| 2024-09-23 | 개시 | Morgan Stanley | Overweight |
| 2024-05-21 | 개시 | JP Morgan | Overweight |
| 2024-04-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2023-07-27 | 개시 | Piper Sandler | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2023-02-28 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | Guggenheim | Buy |
| 2023-02-28 | 개시 | Jefferies | Buy |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
How (GPCR) Movements Inform Risk Allocation Models - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Shares Down 7.5%Should You Sell? - MarketBeat
Why Structure Therapeutics Shares Are Tumbling Today - TipRanks
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
What is HC Wainwright's Forecast for GPCR FY2027 Earnings? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III - MarketBeat
Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics Oral GLP-1 Obesity Drug Achieves ‘Injectable-Like Efficacy’ in Phase 2 Test - MedCity News
Structure Therapeutics’ Stock Climbing Amid 44-Week Trial Data Buzz - StocksToTrade
William Blair reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Structure Therapeutics (NASDAQ:GPCR) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Given New $100.00 Price Target at HC Wainwright - MarketBeat
Structure Therapeutics (GPCR) Stock Surges 10% as GLP-1 Pill Outperforms Lilly and Novo - CoinCentral
Leerink reiterates Outperform on Structure Therapeutics stock - Investing.com
Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results - TipRanks
Structure Therapeutics Inc Reports Positive Topline Data From Phase 2 ACCESS II Trial With Once-Daily Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron - marketscreener.com
Structure Therapeutics (NASDAQ: GPCR) shows 16% weight loss in Phase 2 oral GLP-1 trial - Stock Titan
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron - Bitget
Why Structure Therapeutics Shares Are Sliding Today - TipRanks
HighVista Strategies LLC Acquires 149,615 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
First Light Asset Management LLC Boosts Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
ArrowMark Colorado Holdings LLC Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by Casdin Capital LLC - MarketBeat
Baker BROS. Advisors LP Sells 952,658 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
Assessing Structure Therapeutics (GPCR) Valuation After Its Quarterly Profit Turnaround - Sahm
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Why Structure Therapeutics (GPCR) Is Down 7.6% After Swinging to Q4 Profit and Filing a $236M Shelf RegistrationAnd What's Next - Sahm
Jefferies Financial Group Inc. Acquires New Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Structure Therapeutics inks major GLP-1 licensing deal - MSN
Rhenman & Partners Asset Management AB Purchases 45,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Trading Systems Reacting to (GPCR) Volatility - Stock Traders Daily
Research Analysts Offer Predictions for GPCR Q1 Earnings - Defense World
Tax withholding trims Structure Therapeutics (NASDAQ: GPCR) CMO stake - Stock Titan
Structure Therapeutics (GPCR) CSO has 18,735 shares withheld for taxes - Stock Titan
Structure Therapeutics (GPCR) CFO logs tax-withholding share disposition - Stock Titan
Structure Therapeutics (GPCR) CDO reports tax share and ESPP transactions - Stock Titan
Structure Therapeutics (GPCR) CEO reports tax share withholding and large trust-held stake - Stock Titan
HC Wainwright Issues Negative Estimate for GPCR Earnings - MarketBeat
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? - TradingView
Structure Therapeutics (GPCR) CTO has shares withheld to cover RSU taxes - Stock Titan
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million - AOL.com
GPCR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Handelsbanken Fonder AB Sells 212,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Upstream Bio, Inc. (UPB) and Cogent Biosciences (COGT) - The Globe and Mail
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position - AOL.com
H.C. Wainwright raises Structure Therapeutics price target on competitive positioning - Investing.com South Africa
Structure Therapeutics Inc Adr (GPCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):